Published in Oncogene on January 29, 2007
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Integrative genome comparison of primary and metastatic melanomas. PLoS One (2010) 1.97
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res (2014) 1.70
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget (2013) 1.32
Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proc Natl Acad Sci U S A (2009) 1.27
The Highly Homologous T-Box Transcription Factors, TBX2 and TBX3, Have Distinct Roles in the Oncogenic Process. Genes Cancer (2010) 1.23
A melanoma molecular disease model. PLoS One (2011) 1.15
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology (2012) 1.04
Integrative genomics identifies gene signature associated with melanoma ulceration. PLoS One (2013) 0.95
The retinoblastoma protein modulates Tbx2 functional specificity. Mol Biol Cell (2010) 0.92
KIT is a frequent target for epigenetic silencing in cutaneous melanoma. J Invest Dermatol (2014) 0.91
Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. Genes Chromosomes Cancer (2009) 0.89
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. J Invest Dermatol (2015) 0.88
Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies. J Cell Mol Med (2009) 0.88
Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. BMC Clin Pathol (2008) 0.86
The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle (2012) 0.86
Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma. Exp Dermatol (2013) 0.84
The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3. J Biol Chem (2014) 0.84
Molecular testing in melanoma. Cancer J (2012) 0.83
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clin Exp Metastasis (2013) 0.82
Novel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool. PLoS One (2010) 0.81
Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression. ISRN Dermatol (2012) 0.81
Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest (2014) 0.81
Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract (2010) 0.80
MiTF links Erk1/2 kinase and p21 CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells. Mol Cancer (2010) 0.80
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res (2015) 0.80
Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets. Oncoimmunology (2013) 0.78
TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle. Oncogene (2015) 0.78
Mechanisms of chromosomal instability in melanoma. Environ Mol Mutagen (2014) 0.77
Variations of BRAF mutant allele percentage in melanomas. BMC Cancer (2015) 0.75
Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology. J Invest Dermatol (2013) 0.75
NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol Oncol (2017) 0.75
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med (2001) 16.65
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res (2001) 8.34
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer (1995) 4.59
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia (2006) 2.45
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res (2000) 2.43
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res (1996) 2.43
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst (2000) 2.41
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet (1997) 2.33
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol (1998) 2.24
Indicators of prognosis in node-negative breast cancer. N Engl J Med (1990) 2.23
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet (2001) 2.19
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer (1998) 2.06
Ginger treatment of hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol (1991) 2.06
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol (2000) 2.01
Towards the phylogeny of APS reductases and sirohaem sulfite reductases in sulfate-reducing and sulfur-oxidizing prokaryotes. Microbiology (1997) 2.00
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res (2000) 1.86
Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer (1997) 1.82
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer (1999) 1.82
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res (1997) 1.82
Virulence factors and pap genotype in Escherichia coli isolates from women with acute pyelonephritis, with or without bacteremia. Clin Infect Dis (1993) 1.78
Sirohaem sulfite reductase and other proteins encoded by genes at the dsr locus of Chromatium vinosum are involved in the oxidation of intracellular sulfur. Microbiology (1998) 1.75
Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet (2005) 1.71
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet (1996) 1.69
Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res (2001) 1.66
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A (2000) 1.66
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Symptomatic urinary tract infection in women in primary health care. Bacteriological, clinical and diagnostic aspects in relation to host response to infection. Scand J Prim Health Care (1996) 1.56
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res (1996) 1.55
Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics (1999) 1.52
In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem (2001) 1.51
Effects of subminimal inhibitory concentrations of ampicillin, chloramphenicol, and nitrofurantoin on the attachment of Escherichia coli to human uroepithelial cells in vitro. Rev Infect Dis (1980) 1.51
The Autism Birth Cohort: a paradigm for gene-environment-timing research. Mol Psychiatry (2010) 1.51
Selective urological evaluation in men with febrile urinary tract infection. BJU Int (2001) 1.50
A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain. Genes Chromosomes Cancer (1999) 1.49
A protein kinase antigenically related to pp60v-src possibly involved in yeast cell cycle control: positive in vivo regulation by sterol. Proc Natl Acad Sci U S A (1987) 1.47
Melanoma and nonmelanoma skin cancer in patients with multiple tumours--evidence for new syndromes in a population-based study. Br J Dermatol (2004) 1.46
Effect of a sustained silver-releasing dressing on ulcers with delayed healing: the CONTOP study. J Wound Care (2006) 1.45
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene (2010) 1.43
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol (1999) 1.42
A dissimilatory sirohaem-sulfite-reductase-type protein from the hyperthermophilic archaeon Pyrobaculum islandicum. Microbiology (1998) 1.41
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood (1998) 1.41
Identification of novel candidate genes associated with cleft lip and palate using array comparative genomic hybridisation. J Med Genet (2007) 1.40
[A proposal for new values in significant bacteriuria]. Lakartidningen (1992) 1.39
Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy. Clin Lab Haematol (2005) 1.39
BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res (1998) 1.37
Enzymology and molecular biology of prokaryotic sulfite oxidation. FEMS Microbiol Lett (2001) 1.37
Comparison of urine and serum concentrations of interleukin-6 in women with acute pyelonephritis or asymptomatic bacteriuria. J Infect Dis (1992) 1.34
Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer (1997) 1.34
Assignment of an autosomal sex reversal locus (SRA1) and campomelic dysplasia (CMPD1) to 17q24.3-q25.1. Nat Genet (1993) 1.33
Sulfite:Cytochrome c oxidoreductase from Thiobacillus novellus. Purification, characterization, and molecular biology of a heterodimeric member of the sulfite oxidase family. J Biol Chem (2000) 1.31
A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet (2000) 1.29
Sulfide oxidation in the phototrophic sulfur bacterium Chromatium vinosum. Arch Microbiol (1998) 1.28
Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer (2007) 1.27
Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand (2004) 1.27
Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 1.27
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet (2000) 1.27
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer (2004) 1.26
Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol (1999) 1.24
Mutation analysis in glutaric aciduria type I. J Med Genet (2000) 1.23
Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol (2000) 1.22
HER2/neu amplification and comedo type breast carcinoma. Lancet (1989) 1.22
Incidence, predisposing factors and manifestations of invasive Haemophilus influenzae infections in adults. Eur J Clin Microbiol (1984) 1.20
Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer (1999) 1.17
Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. Br J Cancer (1990) 1.17
Multiple origins for phenylketonuria in Europe. Am J Hum Genet (1992) 1.17
MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res (2000) 1.16
Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene (2006) 1.15
Case-control study of risk factors for cervical neoplasia in Denmark. I: Role of the "male factor" in women with one lifetime sexual partner. Int J Cancer (1991) 1.15
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A (1996) 1.14
Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res (2000) 1.13
Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol (2000) 1.12
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res (1998) 1.12
Molecular heterogeneity of classical and Duarte galactosemia: mutation analysis by denaturing gradient gel electrophoresis. Hum Mutat (1997) 1.11
Virulence factors of Escherichia coli in urinary isolates from pregnant women. J Infect Dis (1987) 1.10
Evidence for two pathways of thiosulfate oxidation in Starkeya novella (formerly Thiobacillus novellus). Arch Microbiol (2001) 1.10
Congenital heart disease in maternal phenylketonuria: report from the Maternal PKU Collaborative Study. Pediatr Res (2001) 1.09
Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res (1999) 1.07
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia (2005) 1.07
Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Genes Chromosomes Cancer (1999) 1.07
Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer (2000) 1.07
Flagellate erythema due to bleomycin. Br J Haematol (2008) 1.05
Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Dis Markers (1999) 1.05
Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem (2001) 1.05
Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat (1998) 1.05
Myocardial injury from transthoracic defibrillator countershock. Arch Pathol (1975) 1.04